Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
International Stem Cell (ISCO)
OTHER OTC:ISCO
Holding ISCO?
Track your performance easily
ISCO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.05 - $0.15
Previous Close$0.09
Volume2.02K
Average Volume (3M)6.98K
Market Cap
$842.46K
Enterprise Value$3.41M
Total Cash (Recent Filing)$1.31M
Total Debt (Recent Filing)$3.88M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
May 16, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding8,004,389
10 Day Avg. Volume6,812
30 Day Avg. Volume6,980
Standard Deviation0.30
R-Squared0.00056
Alpha0.00375
Financial Highlights & Ratios
Price to Book (P/B)-0.21
Price to Sales (P/S)0.10
Price to Cash Flow (P/CF)0.80
P/FCF Ratio0.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.40
Enterprise Value/Gross Profit0.74
Enterprise Value/Ebitda-284.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Ownership Overview
0.46%
Insiders
<0.01% Other Institutional Investors
99.54% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ISCO FAQ
What was International Stem Cell’s price range in the past 12 months?
International Stem Cell lowest stock price was $0.05 and its highest was $0.15 in the past 12 months.
What is International Stem Cell’s market cap?
Currently, no data Available
When is International Stem Cell’s upcoming earnings report date?
International Stem Cell’s upcoming earnings report date is May 16, 2024 which is 190 days ago.
How were International Stem Cell’s earnings last quarter?
International Stem Cell released its earnings results on Apr 09, 2024. The company reported -$0.057 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.057.
Is International Stem Cell overvalued?
According to Wall Street analysts International Stem Cell’s price is currently Overvalued.
Does International Stem Cell pay dividends?
International Stem Cell does not currently pay dividends.
What is International Stem Cell’s EPS estimate?
International Stem Cell’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does International Stem Cell have?
International Stem Cell has 8,004,389 shares outstanding.
What happened to International Stem Cell’s price movement after its last earnings report?
International Stem Cell reported an EPS of -$0.057 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 11.111%.
Which hedge fund is a major shareholder of International Stem Cell?
Currently, no hedge funds are holding shares in ISCO
---
International Stem Cell Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.82%
12-Months-Change
Fundamentals
Return on Equity
-210.00%
Trailing 12-Months
Asset Growth
-8.17%
Trailing 12-Months
Company Description
International Stem Cell
International Stem Cell Corp. is a clinical stage biotechnology company, which engages in the development of therapeutic and biomedical products. It operates through the following segments: Cosmetic Market, Biomedical Market, and Therapeutic Market. The Cosmetic Market segment develops, manufactures, and markets a cosmetic skin care products based on the company's proprietary parthenogenetic stem cell technology and targeted small molecule technology. The Biomedical Market segment involves in the development, manufacture, and commercialization of primary human cell research products. The Therapeutic Market segment focuses on the research and development of human parthenogenetic stem cells for the treatment of diseases of the central nervous system, liver diseases, and is currently conducting clinical trials for the treatment of Parkinson's disease. The company was founded by William B. Adams, Kenneth C. Aldrich, and Gregory S. Keller on August 17, 2001 and is headquartered in Carlsbad, CA.
---
Technical Analysis
---